BioCity Biopharma is thrilled to announce that the first patient has now been dosed with its pioneering antibody drug conjugate, BC3195, in a Phase 1a/1b clinical trial conducted in China. This is an incredible milestone, representing a significant step towards developing a groundbreaking, modality-independent therapy for cancer and autoimmune disorders.
The trial will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of BC3195 in patients with locally advanced or metastatic solid tumors. We are eager to evaluate the potential of this remarkable therapy in changing the lives of those affected by these conditions.
BC3195 is an revolutionary antibody-drug conjugate (ADC) which targets a glycoprotein, CDH3/P-cadherin, known to be critical for cancer development as it is highly expressed in a variety of different cancers such as lung, breast, gastric, ovarian, colorectal, and pancreatic. The advantage of this ADC is that CDH3 expression is usually absent in healthy tissue, making it a promising tool for attaining cancer-specific targeting.
BC3195 is an exciting new ADC targeting CDH3, which shows great promise in clinical development worldwide. With cell surface CDH3 binding and efficient internalization, BC3195 has a patented, clinically validated cleavable linker and payload (vc-MMAE) which destroys targeted tumor cells as well as those surrounding it in a process known as the bystander effect.
Preclinical animal studies have indicated encouraging safety profiles and powerful antitumor activity with tumor growth inhibition of ≥100%. BC3195 truly offers a transformative new option for cancer patients around the world.
BC3195 is causing a buzz in the medical field – clinical trials of the drug are being conducted both in China and the US! BioCity Biopharma anticipates obtaining preliminary results from their studies by the end of 2023, potentially offering a novel approach to treating medical conditions.
About BioCity
BioCity is an innovative biopharmaceutical company striving to make a lasting impact on the world of cancer and autoimmune therapeutic treatments. Founded in December 2017, the company has built a robust pipeline of more than 10 unique modality-independent drugs, ranging from small molecules to monoclonal antibodies and antibody-drug conjugates (ADCs).
These drugs are being developed to treat cancer and autoimmune diseases, such as chronic kidney diseases (CKD). Being committed to finding treatments that improve patient outcomes, BioCity continues to innovate the medical field with its novel technology and treatments.
BioCity Biopharma is leading the way in innovative oncology treatments, currently advancing six projects in Phase 1 clinical development. Among these cutting-edge therapies is the first-in-Class CDH3-targeting ADC, and agents targeting the DNA damage response (DDR) pathway via a WEE1 and an ATR inhibitor.
In addition, the company is developing treatments to bolster the immune system, including a T cell engager (CD3XEGFR BsAb), an immune checkpoint inhibitor (TIM-3 mAb), and a T cell activator (4-1BB mAb). Beyond oncology, an endothelin A(ETA)-receptor selective antagonist designed for CKD has recently entered Phase 2 trials with great potential for success.